Clinical Pipeline Leverage Cellectar's focus on phospholipid drug conjugates (PDC) and their lead asset iopofosine I 131, plus emerging programs CLR 121125 and CLR 121225, to position strategic collaboration or licensing discussions with radiopharmaceuticals and targeted cancer therapy partners seeking novel, localized delivery with reduced off-target effects.

Radiopharmaceutical Expertise Target opportunities with pharmaceutical and biotech sponsors pursuing targeted radiopharmaceuticals, as Cellectar actively develops iodine-125 and radioisotope delivery programs for solid tumors, offering potential co-development, out-licensing, or milestone-based partnerships.

Phase Progression Monitor CLOVER WaM and other Phase 1/2 programs to identify sponsors or contract research organizations (CROs) interested in collaboration, funding, or access to Cellectar’s data, manufacturing capabilities, and biomarker-driven patient enrichment strategies for faster go/no-go decisions.

Strategic Partnerships Explore collaboration or licensing with larger biotech/pharma players seeking to augment their oncology portfolios with PDC platforms, preclinical PDC programs, and partnered assets to expand the reach of targeted cancer therapies across TNBC, lung, colorectal, pancreatic cancers, and beyond.

Engagement & Visibility Capitalize on ongoing investor and conference activity (ASCO, JP Morgan Healthcare Conference, AACR) to coordinate outreach, arrange meetings with C-level and clinical leads, and present value propositions around improved efficacy and safety profiles through PDC delivery for potential strategic investments or co-development deals.